semaglutide california ban update just got FDA-approved for kidney disease. This changes everything., January 2025. The FDA approved semaglutide (Ozempic/Wegovy) for a new indication: reducing kidney disease progression in FDA moves to remove GLP-1

Can semaglutide improve longevity

GLP-1 RAs are one of the most significant therapeutic advances in the management of type 2 diabetes and obesity over the past decade ( 1 , 2 )

Researchers showed that the risk of intestinal obstruction when taking semaglutide is 4.5 times higher than when receiving other glucose control medications

One significant concern is the concurrent use of Adderall with other central nervous system stimulants or monoamine oxidase inhibitors (MAOIs)

Weeks 13 to 16: the 1.7 mg phase (Wegovy protocol) If you are following the Wegovy weight loss protocol, the dose continues climbing

Two rules: Do not step down semaglutide before switching